John F. Neylan - 02 Mar 2022 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role
Executive Vice President, Chief Medical Officer and Head of Research
Signature
/s/ Jennifer J. Rhodes, as attorney-in fact for John F. Neylan
Issuer symbol
ELTX
Transactions as of
02 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Mar 2022, 15:21:53 UTC
Previous filing
21 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 02 Mar 2022 Common Stock 175,000 $1.99 Direct F1
transaction ELTX Stock Option (Right to Buy) Award $0 +100,000 +57% $0.000000 275,000 02 Mar 2022 Common Stock 100,000 $1.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2 The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022.

Remarks:

Executive Vice President, Chief Medical Officer and Head of Research